The ATM offering creates persistent overhang as shares can be sold at any time into market strength. Monitor daily volume and Jefferies' selling patterns — heavy selling days will pressure the stock. The mid-2026 firmonertinib data readout is the key catalyst; the ATM allows the company to raise capital ahead of that event but at the cost of near-term dilution.
Price Chart
Executive Summary
ArriVent BioPharma filed a 424B5 prospectus supplement for an at-the-market (ATM) offering of up to $250 million in common stock through Jefferies, announced on the same day as its Q1 2026 earnings release. The company reported a net loss of $43.3 million for Q1 2026 (improved from $64.4 million in Q1 2025), with cash and investments of $326.4 million expected to fund operations into Q4 2027. The ATM offering, representing ~18.7% dilution at the current price, provides additional capital for pipeline programs including firmonertinib and ARR-002, but signals near-term shareholder dilution.
Key Facts
- ATM offering of up to $250,000,000 in common stock via Jefferies with up to 3.0% commission
- At $29.50/share, maximum of ~8.47 million shares (18.7% dilution vs. 45.31M shares outstanding)
- Q1 2026 net loss of $43.3 million (improved from $64.4 million in Q1 2025)
- Cash and investments of $326.4 million as of March 31, 2026, funding into Q4 2027
- R&D expenses decreased to $37.6 million from $61.3 million YoY; G&A increased to $8.5 million from $5.5 million
- Net cash used in operations was $41.9 million in Q1 2026 vs. $68.0 million in Q1 2025
- Topline Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion NSCLC expected mid-2026
- IND clearance for ARR-002 (MUC16/NaPi2b ADC) received; first patient dosing expected in 2H 2026
- 1,250,764 shares already sold post-March 31, 2026 under prior ATM facility
Financial Impact
Up to $250 million gross proceeds from ATM offering; immediate dilution of ~$19.38 per share for new investors at assumed $29.50 price; net loss of $43.3 million in Q1 2026
Risk Factors
- Continued dilution from ATM sales at potentially lower prices
- Phase 3 firmonertinib data may disappoint (single pivotal trial risk)
- No approved products or revenue; reliance on pipeline execution
- Cash burn rate of ~$41.9M/quarter may accelerate with expanded trials
- Competition from other EGFR inhibitors and ADCs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-058700 |
| Document: tm2614155d1_ex-filingfees.htm | 0001104659-26-058700 |
| Document: 0001104659-26-058700-index-headers.html | 0001104659-26-058700 |
| Document: 0001104659-26-058700-index.html | 0001104659-26-058700 |
| Document: 0001104659-26-058700.txt | 0001104659-26-058700 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $23.64 | awaiting T+5 | — | $15.38 (−34.94%) |
Oct 25, 2026 2d ago | Press Release | $21.00 | awaiting T+5 | — | $15.38 (−26.76%) |
Oct 23, 2026 3d ago | Press Release | $21.00 | awaiting T+5 | — | $15.38 (−26.76%) |
Oct 19, 2026 8d ago | 8-K | $17.94 $15.36 | ▼ −14.38% | ▼ −14.24% | $15.38 (−14.27%) |
Oct 13, 2026 13d ago | SC 13G | $16.20 $19.12 | ▲ +18.02% | ▲ +17.57% | $15.38 (−5.06%) |
Oct 13, 2026 14d ago | 8-K | $16.09 $18.85 | ▲ +17.15% | ▲ +18.31% | $15.38 (−4.41%) |
Oct 8, 2026 18d ago | SC 13D/A | $16.73 $16.66 | ▲ +0.42% | ▼ −1.55% | $15.38 (+8.07%) |
Oct 6, 2026 21d ago | 8-K | $15.09 $16.09 | ▼ −6.63% | ▼ −6.77% | $15.38 (−1.92%) |
Aug 12, 2026 10w ago | Press Release | $30.00 $29.18 | ▲ +2.73% | ▲ +0.77% | $15.38 (+48.73%) |
Jun 11, 2026 19w ago | Institutional Cluster | $30.54 $31.74 | ▲ +3.93% | ▲ +3.26% | $15.38 (−49.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers